Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement

European Journal of Clinical Pharmacology

Volumn 69, Issue 10, 2013, Pages 1769-1775

  Tan, Sheng Lan ^a,b   Li, Zhi ^a   Zhang, Wei ^a   Song, Guo Bao ^b   Liu, Li Ming ^b   Peng, Juan ^a   Liu, Zhao Qian ^a   Fan, Lan ^a   Meng, Xiang Guang ^c   Wang, Lian Sheng ^a   Chen, Yao ^a   Zhou, Xin Min ^b   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c People's Hospital of Zhengzhou   (China)

Author keywords

CYP2C9; Heart valve replacement; Polymorphisms; POR; VKORC1; Warfarin

Indexed keywords

ALANINE; CYTOCHROME P450 REDUCTASE; VALINE; WARFARIN;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART VALVE REPLACEMENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POR GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; HAPLOTYPES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84884814266     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1544-2     Document Type: Article

References (23)

1. Hirsh J, Fuster V, Ansell J, Halperin JL, American Heart A, American College of Cardiology F (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107(12):1692-1711. doi: 10.1161/01.CIR.0000063575.17904.4E
2. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784-792. doi: 10.1182/blood-2008-04-149070
3. Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ (2010) CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 70(2):234-240. doi: 10.1111/j.1365-2125.2010.03698.x
4. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10(2):261-266. doi: 10.2217/14622416.10.2.261
5. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84(3):326-331. doi: 10.1038/clpt.2008.10
6. International Warfarin Pharmacogenetics C, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753-764. doi: 10.1056/NEJMoa0809329
7. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, Zou XM, Li Q, Ma LQ, Wang HF, Chen BL, Li L, Jia YK, Xu XM (2009) Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 19(3):226-234. doi: 10.1097/FPC.0b013e328326e0c7
8. Hu L, Zhuo W, He YJ, Zhou HH, Fan L (2012) Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenet Genomics 22(11):812-819. doi: 10.1097/FPC.0b013e328358d92b
9. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB (2008) Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 18(1):11-24. doi: 10.1097/FPC.0b013e3282f2f121
10. Huang N, Agrawal V, Giacomini KM, Miller WL (2008) Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 105(5):1733-1738. doi: 10.1073/pnas.0711621105
11. Agrawal V, Choi JH, Giacomini KM, Miller WL (2010) Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 20(10):611-618. doi: 10.1097/FPC. 0b013e32833e0cb5
12. Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, Giacomini KM, Miller WL (2010) Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 20(11):677-686. doi: 10.1097/FPC.0b013e32833f4f9b
13. Dobrinas M, Cornuz J, Pedrido L, Eap CB (2012) Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking. Pharmacogenet Genomics 22(2):143-151. doi: 10.1097/FPC. 0b013e32834e9e1a
14. Zhang X, Li L, Ding X, Kaminsky LS (2011) Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Met Dispos: the biological fate of chemicals 39(8):1433-1439. doi: 10.1124/dmd.111.038836
15. Yang G, Fu Z, Chen X, Yuan H, Yang H, Huang Y, Ouyang D, Tan Z, Tan H, Huang Z, Zhou H (2011) Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. Clin Ther 33(12):2060-2070. doi: 10.1016/j.clinthera.2011.11.004
16. Tan SL, Li Z, Song GB, Liu LM, Zhang W, Peng J, Zhang T, Jia FF, Zhou G, Zhou HH, Zhou XM (2012) Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. Die Pharm 67(11):930-937
17. Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15(2):97-98. doi: 10.1038/sj.cr.7290272
18. Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73(5):1162-1169. doi: 10.1086/379378
19. Nakamura K, Obayashi K, Araki T, Aomori T, Fujita Y, Okada Y, Kurabayashi M, Hasegawa A, Ohmori S, Nakamura T, Yamamoto K (2012) CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. J Clin Pharm Ther 37(4):481-485. doi: 10.1111/j.1365-2710.2011.01317.x
20. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ, International Warfarin Pharmacogenetics C (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18):3827-3834. doi: 10.1182/blood-2009-12-255992
21. Ellis J, Gutierrez A, Barsukov IL, Huang WC, Grossmann JG, Roberts GC (2009) Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering. J Biol Chem 284(52):36628-36637. doi: 10.1074/jbc.M109.054304
22. Agrawal V, Huang N, Miller WL (2008) Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 18(7):569-576. doi: 10.1097/FPC.0b013e32830054ac
23. Tee MK, Huang N, Damm I, Miller WL (2011) Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms. Mol Endocrinol 25(5):715-731. doi: 10.1210/me.2010-0236